Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.66 |
| ▸ | RAF1 | P04049 | 4/20 | 0.66 |
| ▸ | KDM1A | O60341 | 10/20 | 0.60 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676613 | 0.85 | MAP2K1 (0.78) | MAP2K1RAF1KDM1ALRRK2EGFR | |
| SCHEMBL29556194 | 0.85 | MAP2K1 (0.78) | MAP2K1RAF1KDM1ALRRK2EGFR | |
| SCHEMBL15191309 | 0.84 | MAP2K1 (0.62) | MAP2K1RAF1LRRK2EGFRERBB2 | |
| SCHEMBL6382485 | 0.83 | EGFR (0.53) | MAP2K1RAF1KDM1AEGFRERBB2 | |
| SCHEMBL6691519 | 0.81 | MAP2K1 (0.68) | MAP2K1RAF1LRRK2EGFRERBB2 | |
| SCHEMBL6382495 | 0.81 | EGFR (0.47) | MAP2K1RAF1KDM1AEGFRERBB2 | |
| SCHEMBL27707570 | 0.80 | MAP2K1 (1.00) | MAP2K1RAF1LRRK2ERBB2 | |
| SCHEMBL6380345 | 0.79 | EGFR (0.56) | MAP2K1RAF1KDM1AEGFRERBB2 | |
| SCHEMBL12156904 | 0.77 | LRRK2 (0.72) | MAP2K1RAF1LRRK2EGFRERBB2 | |
| SCHEMBL6380353 | 0.77 | EGFR (0.45) | MAP2K1RAF1KDM1ALRRK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263503-B1 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | WYETH CORP (US) | 2005-11-02 | — | — | EP | disclosed |
| CN-1190197-C | Application of cyanoquinoline in preparing medicine for treating or inhibiting colonic polyp | HEWLETT HOLDINGS CORP (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-0973746-B1 | SUBSTITUTED 3-CYANO QUINOLINES | WYETH CORP (US) | 2003-09-24 | — | — | EP | disclosed |
| CN-1121391-C | Substituted 3-cyano quinolines | AMERICAN CYANAMID CO (US) | 2003-09-17 | — | — | CN | disclosed |
| CN-1429126-A | Use of cyanoquinolines for treating or inhibiting colonic polyps | AMERICAN CYANAMID CO (US) | 2003-07-09 | — | — | CN | disclosed |
| EP-1263503-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6384051-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2002-05-07 | — | — | US | disclosed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| CN-1259125-A | Substituted 3-cyanoquinolines | AMERICAN CYANAMID CO (US) | 2000-07-05 | — | — | CN | disclosed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | disclosed |